This trial is based on the preclinical work of Law et al. who created an in vivo model of LMD and LMD treatment using an immunocompetent mouse model with HER2-positive or triple-negative breast cancer (TNBC) LMD (BC-LMD) produced by CSF injection of cancer cells. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.